MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00280-020-04135-8

Медицинская библиотека · Cancer chemotherapy and pharmacology · 2020

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.

Kotaka Masahito, Saito Yoji, Kato Takeshi, Satake Hironaga, Makiyama Akitaka, Tsuji Yasushi, Shinozaki Katsunori, Fujiwara Toshiyoshi, Mizushima Tsunekazu, Harihara Yasushi, Nagata Naoki, Kurihara Naoto, Ando Masahiko, Kusakawa Genichi, Sakai Takumi, Uchida Yugo, Takamoto Mikihiro, Kimoto Saki, Hyodo Ichinosuke

Клиническое исследование II фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN).

METHODS

This randomized, phase IIa trial enrolled stage II/III colon cancer patients who received adjuvant mFOLFOX6 chemotherapy. Participants were randomly allocated to 3 arms in a double-blind manner: placebo (placebo: days 1-3); 1-day ART (ART-123: day 1, placebo: days 2-3); and 3-day ART (ART-123: days 1-3). ART-123 (380 U/kg/day) or placebo was infused intravenously before each 2-week cycle of mFOLFOX6. OIPN was assessed with the Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity-12 (FACT/GOG-Ntx-12) score by participants and the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) by investigators.

RESULTS

Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The least-squares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART (vs. placebo: 7.3 [95% CI 1.9 to12.8, p = 0.009]), and 32.3 with 3-day ART (vs. placebo: 3.4 [95% CI -.1 to 9.0, p = 0.222]). The cumulative incidence of NCI-CTCAE grade ≥ 2 sensory neuropathy at cycle 12 was 64.3% with placebo, 40.7% with 1-day ART (vs. placebo: -23.5 [95% CI -48.4 to 4.0], p = 0.108), and 45.8% with 3-day ART (vs. placebo: -18.5 [95% CI -44.2 to 9.4], p = 0.264). Common adverse events were consistent with those reported with mFOLFOX6; no severe bleeding adverse events occurred.

CONCLUSION

ART-123 showed a potential preventive effect against OIPN with good tolerability. A larger study with 1-day ART is warranted. NCT02792842, registration date: June 8, 2016.

Для цитирования: Kotaka Masahito, Saito Yoji, Kato Takeshi, Satake Hironaga, Makiyama Akitaka, Tsuji Yasushi, Shinozaki Katsunori, Fujiwara Toshiyoshi, Mizushima Tsunekazu, Harihara Yasushi, Nagata Naoki, Kurihara Naoto, Ando Masahiko, Kusakawa Genichi, Sakai Takumi, Uchida Yugo, Takamoto Mikihiro, Kimoto Saki, Hyodo Ichinosuke. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.. Cancer chemotherapy and pharmacology. 2020. DOI: 10.1007/s00280-020-04135-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.